J&J’s advanced bladder cancer drug wins FDA approval

Organisation: Position: Deadline Date: Location:

Johnson & Johnson’s drug Balversa has won US approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration is quoted in a Reuters Health report as saying.

The list price of the drug, known chemically as erdafitinib, will range between $10,080 to $22,680 for a 28-day supply, depending of the dose, J&J said.

Balversa is the first approved drug in a class known as FGFR inhibitors that targets growth factor receptors involved in cell growth and division. The report says the drug is approved for use in patients whose cancer has progressed during or after chemotherapy and have specific genetic alterations known as FGFR3 or FGFR2. Patients will be selected for therapy with Balversa using an FDA-approved companion diagnostic device that will identify the genetic mutations, the agency said.

Bladder cancer is the sixth most common cancer in the US, with the FGFR alterations present in about one in five patients.

“We’re in an era of more personalised or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” Richard Pazdur, head of the FDA’s oncology products division, said in the report.

The approval was based on a small 87-patient trial in which about a third of subjects experienced tumour shrinkage. The median duration before disease progression was 5.4 months.

The report says common side effects of the drug include high phosphate levels, mouth sores and fatigue. The drug may cause serious eye problems, including inflamed eyes, the FDA said.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.